Analyst Ratings for CRISPR Therapeutics
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter:
Goldman Sachs Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $46
Goldman Sachs maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $52 to $46.
Piper Sandler Maintains Overweight on CRISPR Therapeutics, Lowers Price Target to $115
Piper Sandler analyst Edward Tenthoff maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Overweight and lowers the price target from $180 to $115.
Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $53
Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $64 to $53.
Needham Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $122
Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $170 to $122.
CRISPR Therapeutics Announces Oral Presentation Of New Clinical Data On Anti-CD70 Allogeneic CAR-T Therapy CTX130 For Patients With T-Cell Lymphoma At The Annual European Hematology Association 2022 Hybrid Congress
CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid
Oppenheimer Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $150
Oppenheimer analyst Jay Olson maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $172 to $150.
Why This Analyst Has ‘Little Conviction’ On CRISPR’s Upcoming Trial Data
RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics’ (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia…
Chardan Capital Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $168
Chardan Capital analyst Geulah Livshits maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $171 to $168.
SVB Leerink Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $112
SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $120 to $112.